Please assess the completion status of the following clinical trial:

Trial Title: Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate.~* Progressive, metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy (resistant or intolerant).~* Progressive disease based on PSA progression, RECIST, or positive bone scan.~* ECOG 0 or 1.~Exclusion Criteria:~* Prior treatment with sunitinib and/or more than 1 prior chemotherapy regimen in the metastatic disease setting.~* Chemotherapy within 3 weeks.~* Impending complications from bone metastases.~* Ongoing urinary obstruction.~* Cardiac dysfunction, QTc \>470 msec.~* CNS involvement.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Treatment Arm A - sunitinib + prednisone
- B (Type: PLACEBO_COMPARATOR): Treatment Arm B - placebo + prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).